[{"id":"739a6ead-49a8-4524-b971-bdd0dec1f85b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05082025","created_at":"2021-10-18T12:53:16.001Z","updated_at":"2025-02-25T17:25:18.256Z","phase":"Phase 2","brief_title":"Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations","source_id_and_acronym":"NCT05082025","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN deletion","tags":["ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 10/29/2026","primary_completion_date":" 10/29/2026","study_txt":" Completion: 10/29/2026","study_completion_date":" 10/29/2026","last_update_posted":"2024-12-18"},{"id":"a1eea5cb-b85b-4c1a-ad3a-f7312c93e2a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01350180","created_at":"2021-01-18T05:30:58.023Z","updated_at":"2025-02-25T15:05:02.987Z","phase":"","brief_title":"Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis","source_id_and_acronym":"NCT01350180","lead_sponsor":"Dr. Tamim Niazi","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2024-12-10"},{"id":"a47b9baf-315f-4d17-8189-36a9e437a098","acronym":"BORXPTEN","url":"https://clinicaltrials.gov/study/NCT06029998","created_at":"2023-09-08T20:10:19.869Z","updated_at":"2024-07-02T16:35:14.989Z","phase":"Phase 2","brief_title":"Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion","source_id_and_acronym":"NCT06029998 - BORXPTEN","lead_sponsor":"University of Utah","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-13"},{"id":"7d51a185-b11f-400c-ae68-d324a30c60b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02068092","created_at":"2021-01-18T09:31:32.582Z","updated_at":"2024-07-02T16:35:34.116Z","phase":"Phase 2/3","brief_title":"Olive Oil for High Risk Breast Cancer Prevention in Women","source_id_and_acronym":"NCT02068092","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • BRCA mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2023-10-10"},{"id":"914653e2-dfa1-47cf-b128-9f2a0b04b4a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075308","created_at":"2021-01-18T04:14:13.456Z","updated_at":"2024-07-02T16:35:41.030Z","phase":"Phase 2","brief_title":"SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer","source_id_and_acronym":"NCT01075308","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pracinostat (SB939)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 06/28/2010","start_date":" 06/28/2010","primary_txt":" Primary completion: 01/05/2015","primary_completion_date":" 01/05/2015","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"d6c66296-2fa3-4acd-b1bc-50dce3476783","acronym":"PROGECT","url":"https://clinicaltrials.gov/study/NCT02302742","created_at":"2021-01-17T17:54:38.897Z","updated_at":"2024-07-02T16:35:48.688Z","phase":"","brief_title":"Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry","source_id_and_acronym":"NCT02302742 - PROGECT","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • PALB2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • PALB2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1500","initiation":"Initiation: 03/22/2011","start_date":" 03/22/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-05-09"},{"id":"d9d3567e-a116-4764-b0c4-18eb2c09592c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549989","created_at":"2021-01-18T12:20:10.264Z","updated_at":"2024-07-02T16:35:54.941Z","phase":"Phase 2","brief_title":"Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02549989","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3R2","pipe":" | ","alterations":" PTEN deletion","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3R2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2023-02-22"},{"id":"6bac108a-e273-4f77-9c14-c3bf0b7b0eb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05111080","created_at":"2021-11-08T14:53:05.636Z","updated_at":"2024-07-02T16:36:21.042Z","phase":"","brief_title":"Partial PTEN Deletion in Breast Cancer","source_id_and_acronym":"NCT05111080","lead_sponsor":"Assiut University","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2021-11-08"},{"id":"ef0d0fb5-bfa3-47d0-bb81-8a74c2f08ab5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02303327","created_at":"2021-01-18T10:53:33.536Z","updated_at":"2024-07-02T16:36:24.221Z","phase":"Phase 3","brief_title":"Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients","source_id_and_acronym":"NCT02303327","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" PTEN • TMPRSS2","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"],"overall_status":"Recruiting","enrollment":" Enrollment 296","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2021-09-21"},{"id":"ab87f7b8-10f9-4d94-840a-2a5b2223d4c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02573636","created_at":"2021-01-18T12:28:21.038Z","updated_at":"2024-07-02T16:36:39.864Z","phase":"","brief_title":"The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy","source_id_and_acronym":"NCT02573636","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 208","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2020-10-20"},{"id":"1ae6c471-6445-4fd2-b871-72286488e80f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03304990","created_at":"2021-01-18T16:19:29.757Z","updated_at":"2024-07-02T16:36:42.943Z","phase":"","brief_title":"Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)","source_id_and_acronym":"NCT03304990","lead_sponsor":"Greater Baltimore Medical Center","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • VHL","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation • VHL mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation • VHL mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2020-07-22"},{"id":"653c069b-b3fd-4296-9ec6-b61db80cd0e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04001569","created_at":"2021-01-18T19:40:05.431Z","updated_at":"2024-07-02T16:36:58.529Z","phase":"Phase 1/2","brief_title":"AZD8186 and Paclitaxel in Advanced Gastric Cancer","source_id_and_acronym":"NCT04001569","lead_sponsor":"Seoul National University Bundang Hospital","biomarkers":" PTEN • PIK3CB","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AZD8186"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-06-28"},{"id":"a6d7668a-de1a-4dc8-8fcb-764c0dc2a8d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02613923","created_at":"2021-01-18T12:41:56.434Z","updated_at":"2024-07-02T16:36:59.796Z","phase":"","brief_title":"A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer","source_id_and_acronym":"NCT02613923","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • CDH1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/04/2015","start_date":" 08/04/2015","primary_txt":" Primary completion: 03/23/2017","primary_completion_date":" 03/23/2017","study_txt":" Completion: 07/23/2017","study_completion_date":" 07/23/2017","last_update_posted":"2019-05-09"},{"id":"49fbcf0e-3fee-49ef-aec1-7156d3fe1d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01339052","created_at":"2021-01-18T05:27:46.917Z","updated_at":"2025-02-25T15:51:51.879Z","phase":"Phase 2","brief_title":"Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma","source_id_and_acronym":"NCT01339052","lead_sponsor":"Patrick Y. Wen, MD","biomarkers":" PIK3CA • PTEN • PIK3R1","pipe":" | ","alterations":" PIK3CA mutation • PTEN deletion • PTEN mutation","tags":["PIK3CA • PTEN • PIK3R1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN deletion • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-03-19"},{"id":"ab4e13fb-bc17-4b9c-b659-e01415837932","acronym":"","url":"https://clinicaltrials.gov/study/NCT01097278","created_at":"2021-01-18T04:20:21.177Z","updated_at":"2024-07-02T16:37:16.076Z","phase":"Phase 2b","brief_title":"S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer","source_id_and_acronym":"NCT01097278","lead_sponsor":"Southwest Oncology Group","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2017-11-24"},{"id":"89075d7f-c908-44df-b248-9e0bc64aaac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03032614","created_at":"2021-01-18T14:55:37.431Z","updated_at":"2024-07-02T16:37:17.214Z","phase":"Phase 2","brief_title":"Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients","source_id_and_acronym":"NCT03032614","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" BRCA1 • BRCA2 • PTEN","pipe":" | ","alterations":" PTEN deletion • High HRD score","tags":["BRCA1 • BRCA2 • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • High HRD score"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Halaven (eribulin mesylate) • veliparib (ABT-888)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/30/2017","start_date":" 09/30/2017","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 04/30/2020","study_completion_date":" 04/30/2020","last_update_posted":"2017-10-10"},{"id":"ab92c58b-857a-4ca7-8df7-5756e5b815b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923377","created_at":"2021-01-18T03:34:28.787Z","updated_at":"2024-07-02T16:37:20.443Z","phase":"","brief_title":"Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer","source_id_and_acronym":"NCT00923377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • PTEN • BRCA","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 03/23/2007","start_date":" 03/23/2007","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 05/11/2010","study_completion_date":" 05/11/2010","last_update_posted":"2017-07-02"},{"id":"7edccb49-0785-4c46-83e6-3209038aea5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297452","created_at":"2021-01-18T05:16:25.299Z","updated_at":"2025-02-25T15:51:41.758Z","phase":"Phase 1","brief_title":"BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01297452","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN deletion • PTEN mutation","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 02/15/2011","start_date":" 02/15/2011","primary_txt":" Primary completion: 03/29/2017","primary_completion_date":" 03/29/2017","study_txt":" Completion: 03/29/2017","study_completion_date":" 03/29/2017","last_update_posted":"2017-03-31"}]